Development asset linked to ITALFARMACO S.P.A in public FDA and regional records.
pharma · Duchenne muscular dystrophy (DMD) · JAK2V617F-positive high-risk Polycythemia Vera
ITALFARMACO S.P.A
Italfarmaco S.p.A.
ITALFARMACO S.P.A drug portfolio — 17 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Cinisello Balsamo, IT HQ
1938 Founded
629 Employees
EMA registrant Type
Company details
- Status
- Public
- HQ
- Cinisello Balsamo, IT
- Founded
- 1938
- Employees
- 629
- Programs
- 7
- Drugs
- 17
- Patents
- 0
ITALFARMACO S.P.A pipeline
Portfolio lens on 17 drugs and development assets — regulatory status, targets, and deep links to NovaPharmaNews drug profiles.
ITALFARMACO S.P.A drug portfolio — 17 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Drug portfolio
-
-
Development asset linked to ITALFARMACO S.P.A in public FDA and regional records.
-
US regulatory status: approved. Mechanism: Unknown.
- Mechanism
- Unknown
-
Development asset linked to ITALFARMACO S.P.A in public FDA and regional records.
-
Development asset linked to ITALFARMACO S.P.A in public FDA and regional records. Molecular target: Prothrombin.
- Target
- Prothrombin
- Mechanism
- Thrombin inhibitor
-
dabigatran etexilate
Blood and blood forming organs (B01)Blood and blood forming organs (B01) compound in ITALFARMACO S.P.A's portfolio. Mechanism: Thrombin inhibitor.
- Mechanism
- Thrombin inhibitor
-
Development asset linked to ITALFARMACO S.P.A in public FDA and regional records.
-
givinostat
Musculo-skeletal system (M09)Musculo-skeletal system (M09) compound in ITALFARMACO S.P.A's portfolio.
-
US regulatory status: approved. Molecular target: Histone deacetylase.
- Target
- Histone deacetylase
- Mechanism
- Histone deacetylase inhibitor
-
hydroxycarbamide
Antineoplastic and immunomodulating agents (L01)Antineoplastic and immunomodulating agents (L01) compound in ITALFARMACO S.P.A's portfolio. Molecular target: Ribonucleoside-diphosphate reductase RR1.
- Target
- Ribonucleoside-diphosphate reductase RR1
- Mechanism
- Ribonucleoside-diphosphate reductase RR1 inhibitor
-
Development asset linked to ITALFARMACO S.P.A in public FDA and regional records.
-
Development asset linked to ITALFARMACO S.P.A in public FDA and regional records.
-
Development asset linked to ITALFARMACO S.P.A in public FDA and regional records.
-
rivaroxaban
Blood and blood forming organs (B01)US regulatory status: approved. Molecular target: Coagulation factor X.
- Target
- Coagulation factor X
- Mechanism
- Coagulation factor X inhibitor
-
Development asset linked to ITALFARMACO S.P.A in public FDA and regional records.
-
Development asset linked to ITALFARMACO S.P.A in public FDA and regional records.
-
Development asset linked to ITALFARMACO S.P.A in public FDA and regional records.